Syntax Bio
- Headquarters
- Chicago, Illinois
- Employees
- 1–10
- Founded
- 2021
- Business Model
- B2B
- Website
- syntaxbio.com
- Total Funding
- $15.0M
- Last Round
- $15.0M SeedSep 2024
- Rounds
- 1
About
Develops a CRISPR-based platform to program and accelerate stem cell differentiation, enabling scalable regenerative cell therapies for biopharma partners.
Tech & App Stack
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingSign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sep 2024
Investors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free AccountSimilar Companies
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Clinical-stage biopharma developing precision medicines for cancer and other serious diseases usi...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
BridgeBio makes targeted treatments for genetic diseases.